Cell Samples From Patients With Leukemia

NCT01395628 | Completed

• 3 other identifiers: AAML11B13COG-AAML11B13NCI-2011-02863
• Study Type: observational
• Target: 10
• Locations: 0 countries
• Sites: N/A

Brief Summary

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about cancer and the development of drug resistance in patients. It may also help doctors find better ways to treat cancer. PURPOSE: This research trial is studying samples from patients with leukemia.

Conditions

Leukemia

Keywords

chronic phase chronic myelogenous leukemia; childhood acute promyelocytic leukemia (M3); childhood acute myeloid leukemia/other myeloid malignancies; adult acute myeloid leukemia with t(8;21)(q22;q22); adult acute myeloid leukemia with del(5q); adult acute promyelocytic leukemia (M3)

Outcome Measures

Primary Outcomes (3)

• Primary human leukemia samples capable to survive and proliferate in the zebrafish embryo

• In vivo confirmation of anti-proliferative or toxic effects of known chemotherapeutic agents on the transplanted cells

• Effects of novel anticancer drugs and/or their combinations on individual samples

Interventions

in vitro sensitivity-directed chemotherapy DRUG

cell proliferation assay OTHER

fluorescence activated cell sorting OTHER

laboratory biomarker analysis OTHER

microscopy OTHER

Eligibility Criteria

• Age: Up to 30 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Patients diagnosed with myeloid disease.

DISEASE CHARACTERISTICS: * Samples of blood and tissue cells from patients diagnosed with myeloid disease including the following subtypes: * Chronic phase chronic myeloid leukemia (CML), to complement initial studies in the K562 CML cell line * Acute promyelocytic leukemia (APL), to complement initial studies in the NB4 APL cell line * Acute myeloid leukemia (AML) expressing the t(8;21)(q22;q22) translocation, which occurs in approximately 12% of pediatric AML and is associated with good prognosis * AML expressing 5q- or monosomy 7, associated with a poor prognosis * AML expressing the fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD), associated with a poor prognosis PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Children's Oncology Group: lead
• National Cancer Institute (NCI): collaborator

Biospecimen

Retention: SAMPLES WITH DNA

cell samples

MeSH Terms

Conditions

Leukemia; Leukemia, Myeloid, Chronic-Phase; Leukemia, Promyelocytic, Acute

Interventions

Flow Cytometry; Microscopy

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Myeloproliferative Disorders; Bone Marrow Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Leukemia, Myeloid, Acute

Intervention Hierarchy (Ancestors)

Cell Separation; Cytological Techniques; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Cytophotometry; Fluorometry; Luminescent Measurements; Photometry; Chemistry Techniques, Analytical; Investigative Techniques; Diagnostic Imaging

Study Officials

• Jason N. Berman, MD

  IWK Health Centre

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 14, 2011
• First Posted: July 15, 2011
• Study Start: July 1, 2011
• Primary Completion: May 1, 2016
• Last Updated: May 19, 2016

Record last verified: 2016-05